Af­ter a trend­set­ting role in glob­al biotech ven­ture in­vest­ing, David Mott parts ways with NEA

About 12 years ago, David Mott jumped from the CEO suite at Med­Im­mune — af­ter As­traZeneca bought it for $15.6 bil­lion — in­to one of the busiest roles in biotech ven­ture in­vest­ing at New En­ter­prise As­so­ciates.

Now he’s hit­ting the ex­it, which a spokesper­son for NEA says is due to “per­son­al rea­sons” with plans to spend the bulk of his time wth his fam­i­ly. Mo­hamad Makhzou­mi has been named glob­al head of health­care in­vest­ing to re­place him in that top spot at NEA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER